EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Live Birth Outcomes After Extended or Repeated High‐Dose Medroxyprogesterone Acetate Therapy for Fertility‐Sparing Management of Endometrial Neoplasia: A Single‐Center Retrospective Case Series

Akitoshi Yamamura iD, Asuka Okunomiya, Akihiro Yanai, Koji Yamanoi iD, Mana Taki iD, Tsutomu Ohara, Taito Miyamoto iD, Masumi Sunada, Yukiko Okada, Masaki Mandai

Journal of Obstetrics and Gynaecology Research · 2026

DOI: 10.1111/jog.70178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2026. Verfasst von Akitoshi Yamamura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Medroxyprogesterone Acetate, Endometrial Neoplasms, Antineoplastic Agents, Hormonal, Fertility Preservation. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To clarify live birth outcomes among women receiving extended or repeated high‐dose medroxyprogesterone acetate (MPA) therapy for fertility‐sparing management of atypical endometrial hyperplasia or endometrioid carcinoma grade 1.

Methods

We conducted a single‐center retrospective case series of 53 patients undergoing MPA therapy between 2005 and 2023. Patients were stratified into three groups: (i) complete response (CR) within 6 months (standard group), (ii) CR after extended treatment beyond 6 months (extended group), and (iii) CR after MPA retreatment for first intrauterine recurrence (retreatment group). Primary outcome was the live birth rate (LBR). Secondary outcomes included the effect of initial reproductive intentions, interval from CR to conception, recurrence rates, and recurrence‐free interval (RFI).

Results

LBRs were 33% (10/30) in the standard group, 8% (1/12) in the extended group, and 17% (2/12) in the retreatment group. Among eight patients undergoing MPA retreatment for a second or subsequent recurrence, none achieved live birth. Patients with an initial desire for prompt conception had significantly higher LBRs than those without (38% vs. 5%, p < 0.01). Median time from CR to conception leading to live birth was 12 months. Patients achieving live birth had significantly longer RFIs than those without ( p < 0.01).

Conclusions

Live birth is most likely when CR is achieved within 6 months of MPA therapy; nonetheless, extended or repeated MPA treatment may still result in live birth. These findings suggest the importance of appropriate patient selection and careful monitoring during extended or repeated therapy and attempting conception promptly in fertility‐sparing management of endometrial neoplasia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Medroxyprogesterone AcetateEndometrial NeoplasmsAntineoplastic Agents, HormonalFertility PreservationLive BirthEndometrial HyperplasiaCarcinoma, EndometrioidHumansFemaleRetrospective StudiesPregnancyAdult

Stichwörter der Autor:innen

atypical endometrial hyperplasiaendometrial cancerfertilitylive birthmedroxyprogesterone acetate

Substanzen

Medroxyprogesterone AcetateAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Obstetrics and Gynecology, Shizuoka General Hospital, Shizuoka, Japan.

ORCID-Profile: Akitoshi Yamamura, Koji Yamanoi, Mana Taki, Taito Miyamoto

Zitieren

APA

Yamamura, A., Okunomiya, A., Yanai, A., Yamanoi, K., Taki, M., Ohara, T., Miyamoto, T., Sunada, M., Okada, Y., & Mandai, M. (2026). Live Birth Outcomes After Extended or Repeated High‐Dose Medroxyprogesterone Acetate Therapy for Fertility‐Sparing Management of Endometrial Neoplasia: A Single‐Center Retrospective Case Series. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.70178

Vancouver

Yamamura A, Okunomiya A, Yanai A, Yamanoi K, Taki M, Ohara T, et al. Live Birth Outcomes After Extended or Repeated High‐Dose Medroxyprogesterone Acetate Therapy for Fertility‐Sparing Management of Endometrial Neoplasia: A Single‐Center Retrospective Case Series. Journal of Obstetrics and Gynaecology Research. 2026. doi:10.1111/jog.70178

BibTeX
@article{Yamamura2026,
  author = {Yamamura, Akitoshi and Okunomiya, Asuka and Yanai, Akihiro and Yamanoi, Koji and Taki, Mana and Ohara, Tsutomu and Miyamoto, Taito and Sunada, Masumi and Okada, Yukiko and Mandai, Masaki},
  title = {Live Birth Outcomes After Extended or Repeated High‐Dose Medroxyprogesterone Acetate Therapy for Fertility‐Sparing Management of Endometrial Neoplasia: A Single‐Center Retrospective Case Series},
  journal = {Journal of Obstetrics and Gynaecology Research},
  year = {2026},
  doi = {10.1111/jog.70178}
}
Kostenlos starten →